SCHEMBL1679677

SCHEMBL1679677

Cc1ccc(SS(=O)(=O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 1/20 0.59
ALDH1A1 P00352 6/20 0.55
KMT2A Q03164 4/20 0.55
MEN1 O00255 3/20 0.55
L3MBTL1 Q9Y468 3/20 0.55
HPGD P15428 3/20 0.55
HSP90AA1 P07900 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
GAA P10253 2/20 0.42
MAPT P10636 5/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
MMP8 P22894 1/20 0.40
MMP13 P45452 1/20 0.40
TDP1 Q9NUW8 3/20 0.39
HKDC1 Q2TB90 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6551466 0.98 DNMT1 (0.57) DNMT1ALDH1A1KMT2AMEN1L3MBTL1
SCHEMBL367652 0.98 DNMT1 (0.57) DNMT1ALDH1A1KMT2AMEN1L3MBTL1
SCHEMBL3818647 0.98 DNMT1 (0.57) DNMT1ALDH1A1KMT2AMEN1L3MBTL1
SCHEMBL8705730 0.87 ALDH1A1 (0.59) DNMT1ALDH1A1KMT2AMEN1L3MBTL1
SCHEMBL28785463 0.76 ALDH1A1 (0.41) DNMT1ALDH1A1KMT2AMEN1L3MBTL1
SCHEMBL29009430 0.76 CYP2C9 (0.50) ALDH1A1KMT2AMEN1L3MBTL1HPGD
SCHEMBL3240261 0.76 ALDH1A1 (0.56) ALDH1A1KMT2AMEN1L3MBTL1HPGD
P-Xylene SCHEMBL27791681 0.76 GAA (0.58) DNMT1ALDH1A1KMT2AMEN1CYP2C9
P-Xylene SCHEMBL2456088 0.76 GAA (0.58) DNMT1ALDH1A1KMT2AMEN1CYP2C9
SCHEMBL3971967 0.76 ALDH1A1 (0.65) ALDH1A1KMT2AMEN1L3MBTL1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102272212-A Sulfur-containing cycloaliphatic compound, process for its preparation, filled sulfur-vulcanizable elastomer composition containing same and articles fabricated therefrom 2011-12-07 CN claimed
US-20020151570-A1 Thiosulfonic acid S-esters as agents for protecting material BAYER AKTIENGESELLSCHAFT (DE) 2002-10-17 US claimed
EP-0495253-B1 Method for the photographic production of silver images AGFA GEVAERT NV (BE) 1995-05-10 EP claimed
US-5266442-A Method for increasing the contrast of photographic silver images AGFA-GEVAERT N.V. (BE) 1993-11-30 US claimed
EP-0495253-A1 Method for the photographic production of silver images AGFA-GEVAERT N.V. (BE) 1992-07-22 EP claimed
JP-4333841-A None JP disclosed
US-20230174495-A1 TRIAZINANES POSSESSING THIOSULFONATE END-GROUPS AND METHODS OF MAKING THEM FLEXSYS IP HOLDINGS, LLC 2023-06-08 US disclosed
EP-4139285-A1 TRIAZINANES POSSESSING THIOSULFONATE END-GROUPS AND METHODS OF MAKING THEM Flexsys America L.P. (US) 2023-03-01 EP disclosed
US-11230525-B2 Organic sulfur compound, method for preparing same, and pharmaceutical composition for preventing or treating cancer or an inflammatory disease, containing same as active ingredient SOOKMYUNG WOMENS UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2022-01-25 US disclosed
WO-2021216487-A1 TRIAZINANES POSSESSING THIOSULFONATE END-GROUPS AND METHODS OF MAKING THEM FLEXSYS AMERICA L.P. (US) 2021-10-28 WO disclosed
US-20210300865-A1 NOVEL ORGANIC SULFUR COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR AN INFLAMMATORY DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT SOOKMYUNG WOMENS UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2021-09-30 US disclosed
WO-2019143142-A1 NOVEL PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GLIOBLASTOMA 숙명여자대학교 산학협력단 2019-07-25 WO disclosed
JP-H04333841-A PHOTOGRAPHIC PRODUCTION OF SILVER IMAGE AGFA GEVAERT NV 1992-11-20 JP disclosed
EP-0473209-A1 Method of making direct-positive computer output images AGFA-GEVAERT N.V. (BE) 1992-03-04 EP disclosed
EP-0462528-A1 Method for preparing a silver halide emulsion KONICA CORPORATION (JP) 1991-12-27 EP disclosed
EP-0190375-B1 SUBSTITUTED TRIAZOLOPYRIMIDINES AND THEIR USE IN LIGHT-SENSITIVE PHOTOGRAPHIC ELEMENTS AGFA-GEVAERT N.V. (BE) 1989-04-19 EP disclosed
US-4727017-A ANTIFOGGING AGENTS; STABILIZERS AGFA-GEVAERT, N.V. (BE) 1988-02-23 US disclosed
EP-0190375-A1 Substituted triazolopyrimidines and their use in light-sensitive photographic elements AGFA-GEVAERT N.V. (BE) 1986-08-13 EP disclosed
EP-0129527-A2 Vulcanisable rubber composition and compounds useful as stabilising agents for rubber vulcanisates MONSANTO EUROPE S.A./N.V. (BE) 1984-12-27 EP disclosed
US-3977880-A Direct-positive emulsion containing silver halide grains internally doped with metal ions, surface ripened with gold and sulfur compound and fogged by light exposure FUJI PHOTO FILM CO., LTD. (JA) 1976-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174495-A1 TRIAZINANES POSSESSING THIOSULFONATE END-GROUPS AND METHODS OF MAKING THEM TST, ARSA, TERT DNMT1 1734/4885ALDH1A1 174/4885KMT2A 3001/4885
US-11230525-B2 Organic sulfur compound, method for preparing same, and pharmaceutical composition for preventing or treating cancer or an inflammatory disease, containing same as active ingredient HDAC1, HDAC2, HDAC11 DNMT1 517/4885ALDH1A1 532/4885KMT2A 164/4885
US-20020151570-A1 Thiosulfonic acid S-esters as agents for protecting material TST, STS, SULT1E1 DNMT1 4115/4885ALDH1A1 203/4885KMT2A 4531/4885
US-20210300865-A1 NOVEL ORGANIC SULFUR COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR AN INFLAMMATORY DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT HDAC1, HDAC2, HDAC11 DNMT1 536/4885ALDH1A1 658/4885KMT2A 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.